Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isavuconazonium sulfate PK in pediatric patients
NCT03241550Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2017
- Primary completion
- Jul 2019
- Modality
- Prodrugs/Conditional Activator Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of isavuconazonium in invasive aspergillosis (IA) and mucormycosis (5 cohorts), sponsored by Astellas Pharma. Primary endpoints: Maximum Plasma Concentration at steady state up to 7 days, Area Under the Curve over the dosing interval up to 7 days and 10 more. Started Oct 2017; status: completed.
02
Drugs
isavuconazonium
03
Conditions
invasive aspergillosis (IA)mucormycosis
Beyond the preview
Go deeper on NCT03241550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03241550.